The latest research on stem cells in the treatment of glaucoma is that transplant mesenchymal stem cells into glaucoma model cell to stimulate cell proliferation and tissue regeneration. The success of this study provides a new idea for the future of glaucoma treatment, and helps the majority of patients with glaucoma to retrieve their vision.
Mesenchymal stem cell ( MSCs ) therapy is a research branch of stem cell therapy. Mesenchymal stem cells have strong potential ability of proliferation and differentiation, in vivo or in suitable vitro environment. They are capable of not only differentiate into hematopoietic cells but also differentiate into muscle cells, liver cells, osteoblasts, chondrocytes, stromal cells, etc.
Besides treating the leukemia and the refractory anemia, mesenchymal stem cells also used for cardiovascular disease, cirrhosis of the liver, bone and muscle degenerative diseases, the brain and spinal cord injury, Alzheimer’s, lupus, scleroderma and other autoimmune diseases.
Currently, clinical studies of mesenchymal stem cells have been carried out in many countries. With the development of mesenchymal stem cells research and related technologies, the United States approved more than 40 clinical trials about MSC. China has approved a number of clinical trials, too.
In 2013, Dr. Yu, Professor of Chinese Medical University, gave an academic report, titling ” the basic research and clinical applications of mesenchymal stem cells”, in the cell therapy technology seminar. She shared the research efficacy mechanism of MSCs derived from the mesoderm in clinical trials
This article is contributed by ReLife International Medical Center. For more details on the stem cell therapy provided, please kindly consult us. We are happy to provide a medical solution for your inquiry.